Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
50 Cards in this Set
- Front
- Back
Carbonic Anhydrase
|
Inhibit CA in proximal tubule
decrease bicarb absorptiond decrease H+ for Na/H exchange increase Na excretion in proximal tubule increase Na/K exchange in distal tubule increase K excretion in distal tubule |
|
Loop diuretics mechanisms
|
Blocks Na/K/Cl cotransporter in the thick ascending loop of henle
Increased Na/K/Mg/Ca++(?)/H+ excretion |
|
Thiazides mech.
|
Maintains K/ATP chanels open to inhibit Na+ reabsorption in distal convoluted tubule
|
|
K+sparing mechanism
|
inhibit Na/K exchange in collecting ducts
increase Na excretion |
|
Aldosterone antagonist mechanism
|
competitive inhibitor of aldosterone
|
|
Osmotic diuretics mechanism
|
decrease H2O reabsopriton at the proximal tubule of the loop of henle
increase osmolarity of the TUBULAR fluid |
|
ADH antagonis mech
|
blocks efect of ADH
|
|
Digitalis mechanism
|
Heart: inhibits Na/K atpase
increase intracellular Na+ increase Ca+ expulsion increased intracellular Ca Increase Contractility, CO, decrease HR |
|
Calcium sensitizer Mech
|
increase sensitivity to Ca+ w/o ca++ increase
|
|
PDEI mechanism
|
inhibit phsophodiesterase, which breaks down cAMP
increased cAMP= increased contractility, diastolic function |
|
Sympathomimetics mechanism
|
B1 Agonist
Increase sympatheic activity |
|
BNP mechanism
|
mimics physiologic BNP
|
|
ACE inhibitor Mechanism
|
inhibit ACE which converts ANGI to ANGII
|
|
ARB mechanism
|
Block ANGII receptor
decrease preload/afterload/remodeling |
|
B blocker mechanism
|
decrease adrenergic (sympathetic) activity to the heart
|
|
Vaso D mechanism
|
decrease preload through VenoD
decrease afterload through ArterioD (A=A) |
|
Class IA antiarrrhythmia mechanism
|
Blocks open and activated Na channels
increase ERP |
|
Class IB antiarrhytmia mechanism
|
blocks inactivated Na channels (the slow ones that determine the length of the plateau phase (2), shortens it)
Decrease ERP |
|
Class IC antiarrhythmia mechanism
|
Blocks all sodium channels
no change to ERP |
|
Class II antiarrhytmia mechanism
|
BBlocker
decrease adrenergic activity to the heart |
|
Class III antiarrhythmia mechanism
|
Block K+ channels on repolarization
extend ERP |
|
Class IV antiarrhythmia mechanism
|
Block slow cardiac Ca++ channels
Decrease HR, contractility |
|
Adenosine antiarrhytmia mechanism
|
increase K+ conductance,
inhibit cAMP induced Ca+ influx |
|
K+ antiarrhytmia mechanims
|
Increased or deceased K+ is arrhythmogenic
|
|
Centrally acting sympatholytics mechanism
|
all have the equivalent effect of an a2 agonist
stimulate medullary a2 receptors to change BP set point |
|
Adrenergic neuron blocking agent mechanism
|
block release of NT
sympatholytic |
|
a1 blocking agent mechanism
|
block a1 w/o effect on a2
sympatholytic |
|
nitrates/ites mechanism
|
nitrite ion -> NO ->cGMP -> VasoD
increase coronary flow and distribution |
|
Ranolazine mechanism
|
inhibits pFOX- late Na current
decrease LV wall stiffness FOX RAN LATE |
|
Bosentan mechanism
|
endothelial receptor 1A/B antagonist
endothelins contract smm |
|
Bile acid binding Resin mechanism
|
binds bile acids to decresaeinterstitial absorption
|
|
Nicotinic Acid Mechanism
|
inhibits lipoprotein synthesis
inhibits LDL secretion from the liver/hepatic cholesterogenesis |
|
Statin Mechanism
|
Inhibit HMG CoA reductase,
decrease LDL synthesis, triglycerides increase high affinity LDL receptor, HDL cholesterol |
|
Fibric Acid Derivative Mechanism
|
Ligand for transcription factor PPAR-a, increase LPL activity
Increase VLDL catabolism |
|
Zetia mechanism
|
decreased cholesterol absorption (blocks it)
combine w/statin for synergistic effect |
|
Xenical mechanism
|
Blocks pancreatic lipase
decrease triglycerides breakdown in SI |
|
Heparin sulfate mechanism
|
HMWH
ATIII accelerant increase PTT time |
|
Lepirdi anticoagulant mechanism
|
Thrombin inhibitor
renal excretion |
|
Enoxaparin (lovenox) mechanism
|
Anticoagulant
LMWH |
|
Argatroban
|
direct thrombin inhibitor
liver metabolism |
|
Warfarin mechanism
|
Vit K analog (blocks vit K)
decrease II, VII, IX, X initially increases clotting |
|
Protamine sulfate
|
Anticoagulant reversal drug
Heparin antagonist (wo heparin= anticoagulation) |
|
Vitamin K1
|
Warfarin reversal
|
|
Fibrinolytic agents mechanism
|
all activate plasminogen
TPA and ASEs |
|
Aminocaproic acid
|
antifibrinolytic agent
inhibits plasminogen activation |
|
Aspirin
|
antiplatelet drug
decreased platelet aggregation irrev3ersible for life of platelet |
|
Clopidogrel (plavix)
|
Oral antiplatelet
inhibits ADP in platelets |
|
Abciximab
|
Antiplatelet
IV; inhibits GPIIb/IIIa |
|
Eptifibatide (integrillin)
|
Antiplatelet
IV; inhibits GPIIb/IIIa ratlesnake venom derived |
|
Tirofaban (aggrastat)
|
IV:
inhibits GPIIb/IIIa |